OsteoarthritisNCT07901790
Autologous Adipose-Derived Stem Cell Injections for Knee Osteoarthritis
A study testing Autologous Adipose-Derived Mesenchymal Stem Cells (ADMSCs) and Cross-linked Hyaluronic Acid (Synovian) in people with Osteoarthritis and Knee, run by Yonsei University at 3 sites in South Korea.
Trial summary
This multicenter, prospective, randomized, active-controlled, single-blind (assessor-blinded) clinical trial aims to evaluate the efficacy and safety of intra-articular injection of autologous adipose-derived mesenchymal stem cells (ADMSCs) compared with active comparator hyaluronic acid (HA) in patients with… Read more about this study
- Who is it for?
- Ages 40 to 70 years
- Conditions the study is for
- Osteoarthritis, Knee, Knee Osteoarthritis
- What is being tested?
- Autologous Adipose-Derived Mesenchymal Stem Cells (ADMSCs) and Cross-linked Hyaluronic Acid (Synovian)
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 165 participants
- Where
- 3 sitesSouth Korea
- Study dates
- 3 Sep 2026to 31 May 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults aged 40 to 70 years at the time of written informed consent.
- Knee osteoarthritis diagnosed according to American College of Rheumatology (ACR) criteria with persistent knee pain for at least 3 months.
- Radiographic Kellgren-Lawrence (KL) grade II or grade III in the target knee.
- Activity pain score of >= 40 mm on a 100-mm Visual Analog Scale (VAS) in the target knee.
- Unilateral or bilateral knee OA. In bilateral cases, one target knee must be designated according to criteria 1-4 (if both knees meet criteria, the more painful/symptomatic knee is selected).
- Voluntary provision of written informed consent.
Who cannot join
- Secondary knee osteoarthritis caused by infection, rheumatoid arthritis, or inflammatory joint disease.
- Pain caused by meniscus posterior horn root tear within 3 months prior to screening.
- Pain judged to be caused by subchondral insufficiency fracture or osteonecrosis.
- Conditions affecting joint pain or prognosis (e.g., gout, pseudogout, periarticular fracture, hemochromatosis, Wilson's disease, hypermobility, collagen gene disorders).
- Body Mass Index (BMI) >= 35 kg/m2.
- Prior total knee arthroplasty (TKA) or unicompartmental knee arthroplasty (UKA) in the target knee (prior HTO or partial meniscectomy >= 6 months with stable status is permitted).
Show all 16Show fewer
- Recent target knee treatments: cross-linked HA, cell therapy, or gene therapy within 6 months; linear HA or intra-articular corticosteroid within 3 months; oral NSAIDs, glucosamine, chondroitin, or oral steroids within 14 days prior to injection.
- Uncontrolled type 1 or type 2 diabetes (HbA1c > 8.5% at screening).
- Positive test for Human Immunodeficiency Virus (HIV) antibody.
- History of malignant neoplasm within 3 years prior to screening.
- Participation in another clinical trial within 60 days prior to screening.
- Clinically significant abnormal screening laboratory findings.
- Psychiatric disorder, alcohol/drug abuse affecting adherence or safety.
- Pregnant or breastfeeding women.
- Women of childbearing potential or men unwilling to use medically acceptable contraception during the trial.
- Judged ineligible by the investigator.
Trial locations and contacts
3 sites in 1 country. Contact the study team or a site near you to ask about taking part.
South Korea3 sites, 3 recruiting
- Recruiting
Inha University Hospital
Incheon
Dong-Jin Ryu, Professor, +82-10-4112-7127, jhdms7827@gmail.com
- Recruiting
Seoul National University Hospital
Seoul
Byung-Sun Choi, Professor, +82-10-8763-1007, harufox@snu.ac.kr
- Recruiting
Severance Hospital
Seoul
Sung-Hwan Kim, M.D., Ph.D., +82-2-2228-5679, orthohwan@gmail.com
About this study
Official title: Efficacy and Safety of Intra-articular Autologous Adipose-Derived Mesenchymal Stem Cell Injections for Improving Clinical Function in Patients With Knee Osteoarthritis: A Multicenter, Prospective, Randomized, Active-Controlled Trial
This multicenter, prospective, randomized, active-controlled, single-blind (assessor-blinded) clinical trial aims to evaluate the efficacy and safety of intra-articular injection of autologous adipose-derived mesenchymal stem cells (ADMSCs) compared with active comparator hyaluronic acid (HA) in patients with Kellgren-Lawrence grade II to III knee osteoarthritis. A total of 165 participants across 3 centers (Severance Hospital, Seoul National University Hospital, Inha University Hospital) will be randomly allocated to either the ADMSC group (1.0 x 10^8 cells, single injection) or the HA group (Synovian, 3 mL) in a 2:1 ratio and followed for 6 months post-injection.
Read the detailed description
Osteoarthritis (OA) is a prevalent degenerative joint disease characterized by progressive loss of articular cartilage, chronic pain, and joint dysfunction. Autologous adipose-derived mesenchymal stem cells (ADMSCs) offer potential cartilage protective and anti-inflammatory properties. In this confirmatory trial, 165 eligible adults aged 40 to 70 years with radiographic KL grade II or III knee OA and persistent pain (VAS >= 40 mm) will undergo abdominal fat harvest. Participants will be randomized 2:1 to receive either an ultrasound-guided intra-articular injection of autologous ADMSCs (1.0 x 10^8 cells suspended in 3 mL CryoStor 10) or high molecular weight cross-linked hyaluronic acid (Synovian 3 mL). Follow-up visits occur at 1, 3, and 6 months post-injection. The primary endpoint is the change from baseline in the WOMAC total score at 6 months. Secondary endpoints include changes in WOMAC subscales, VAS pain, KOOS subscores, responder rates (OMERACT-OARSI and MCID), structural outcomes on MRI (MOCART 2.0, MOAKS) and X-ray, rescue medication usage, exploratory synovial/serum biomarkers (COMP, CTX-II), and comprehensive safety profiles through 6 months. After completing the 6-month evaluation, participants allocated to the control group are offered autologous ADMSC injection.
- Conditions
- Osteoarthritis, Knee, Knee Osteoarthritis
- Being tested
- Autologous Adipose-Derived Mesenchymal Stem Cells (ADMSCs), Cross-linked Hyaluronic Acid (Synovian)
- Keywords
- Knee Osteoarthritis, Mesenchymal Stem Cells, Adipose-Derived Stem Cells, Intra-articular Injection, Hyaluronic Acid, WOMAC, Cartilage Regeneration
- Medical subject headings
- Osteoarthritis, Osteoarthritis, Knee
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Autologous Adipose-Derived Mesenchymal Stem Cells (ADMSCs)Biological
Also called ADMSCs, Autologous Adipose-derived Stem Cells, ADSC Intra-articular Injection
Single intra-articular injection of 1.0 x 10^8 culture-expanded autologous ADMSCs suspended in 3 mL cryopreservation medium (CryoStor 10) under ultrasound guidance.
Cross-linked Hyaluronic Acid (Synovian)Drug
Also called Synovian, High molecular weight crosslinked HA, Hyaluronic Acid
Single intra-articular injection of 3 mL high molecular weight cross-linked hyaluronic acid (Synovian Inj., LG Chem) administered under ultrasound guidance.
| Study group | Role | What they receive |
|---|---|---|
| Autologous ADMSC Injection | Experimental | Arm Description: Participants receive a single ultrasound-guided intra-articular injection of autologous adipose-derived mesenchymal stem cells (1.0 x 10^8 cells/3 mL CryoStor 10) isolated and culture-expanded from the participant's abdominal subcutaneous adipose tissue. Receives: Biological: Autologous Adipose-Derived Mesenchymal Stem Cells (ADMSCs) |
| Hyaluronic Acid Injection | Active comparator | Participants undergo identical abdominal liposuction and receive a single ultrasound-guided intra-articular injection of high-molecular-weight cross-linked hyaluronic acid (Synovian 3 mL). At the completion of the 6-month study period, cross-over autologous ADMSC injection is provided. Receives: Drug: Cross-linked Hyaluronic Acid (Synovian) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Total Score at 6 Months
The WOMAC total score assesses pain, stiffness, and physical function on a standardized scale. Higher scores indicate worse pain and functional limitation. The primary efficacy endpoint is the between-group difference in the change from baseline to 6 months post-injection, analyzed using analysis of covariance (ANCOVA).
Measured: Baseline and 6 months post-injection
Secondary outcomes (8)
Change from Baseline in WOMAC Subscale Scores
Changes in individual WOMAC subscales: pain (5 items), stiffness (2 items), and physical function (17 items).
Measured: Baseline, 1, 3, and 6 months post-injection
Change from Baseline in Visual Analog Scale (VAS) Pain Score
Knee pain assessed on a 100-mm Visual Analog Scale (VAS, 0 = no pain, 100 = worst pain).
Measured: Baseline, 1, 3, and 6 months post-injection
Change from Baseline in Knee Injury and Osteoarthritis Outcome Score (KOOS) Subscores
Changes in KOOS subscales (Pain, Symptoms, ADL, Sport/Rec, and QOL; each scored 0-100, where 100 represents no symptoms/best function).
Measured: Baseline, 1, 3, and 6 months post-injection
Proportion of Clinical Responders (MCID and OMERACT-OARSI criteria)
Responder rates evaluated by minimal clinically important difference (MCID: WOMAC >= 9-point reduction, VAS >= 14-mm reduction) and OMERACT-OARSI criteria.
Measured: 6 months post-injection
Magnetic Resonance Imaging (MRI) Assessment of Cartilage
Evaluation of articular cartilage morphologic repair and progression using MOCART 2.0 (Magnetic Resonance Observation of Cartilage Repair Tissue) and MOAKS (MRI Osteoarthritis Knee Score).
Measured: Baseline and 6 months post-injection
Radiographic Progression on Plain Radiographs (X-ray)
Changes in Kellgren-Lawrence (KL) grade and Hip-Knee-Ankle (HKA) mechanical alignment angle.
Measured: Baseline, 3 months, and 6 months post-injection
Rescue Medication Usage
Proportion of participants requiring rescue medication (acetaminophen), cumulative tablet count, and days of rescue medication intake.
Measured: Throughout the 6-month study period
Incidence and Severity of Adverse Events
Incidence, severity, and causality of all adverse events (AEs), serious adverse events (SAEs), and local injection-site reactions according to NCI-CTCAE v6.0 and WHO-UMC criteria.
Measured: Throughout the 6-month study period
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Oct 2026
- Study start3 Sep 2026
- Primary completion29 Feb 2028 (estimated)
- Study completion31 May 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for OsteoarthritisStudies of the same condition, open and under way.
- More trials run by Yonsei UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Parallel assignment with 2:1 randomization ratio to autologous ADMSC injection (1.0 x 10\^8 cells) or active control hyaluronic acid (Synovian) injection.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 165 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Yonsei University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07901790
- Sponsor's protocol ID
- 4-2026-0933
- Status last verified
- Oct 2026
- First submitted
- 22 Oct 2026
- Last updated
- 28 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: The plan to share individual participant data with other researchers has not yet been determined.
Publications
Skidmore S, Hill MA, Bishara K, Konsek H, Kwon JH, Brockbank KGM, Rajab TK. Morbidity and Mortality of Heterotopic Partial Heart Transplantation in Rodent Models. J Cardiovasc Dev Dis. 2023 May 26;10(6):234. doi: 10.3390/jcdd10060234.
PubMed 37367399Servia L, Jove M, Sol J, Pamplona R, Badia M, Montserrat N, Portero-Otin M, Trujillano J. A prospective pilot study using metabolomics discloses specific fatty acid, catecholamine and tryptophan metabolic pathways as possible predictors for a negative outcome after severe trauma. Scand J Trauma Resusc Emerg Med. 2019 May 22;27(1):56. doi: 10.1186/s13049-019-0631-5.
PubMed 31118076Walshe EA, Romer D, Wyner AJ, Cheng S, Elliott MR, Zhang R, Gonzalez AK, Oppenheimer N, Winston FK. Licensing Examination and Crash Outcomes Postlicensure in Young Drivers. JAMA Netw Open. 2022 Apr 1;5(4):e228780. doi: 10.1001/jamanetworkopen.2022.8780.
PubMed 35467733Wang MK, Chin-Yee B, Lo CK, Lee S, El-Helou P, Alowami S, Gangji A, Ribic C. Crusted scabies in a renal transplant recipient treated with daily ivermectin: A case report and literature review. Transpl Infect Dis. 2019 Jun;21(3):e13077. doi: 10.1111/tid.13077. Epub 2019 Mar 29.
PubMed 30873722Jo CH, Lee YG, Shin WH, Kim H, Chai JW, Jeong EC, Kim JE, Shim H, Shin JS, Shin IS, Ra JC, Oh S, Yoon KS. Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a proof-of-concept clinical trial. Stem Cells. 2014 May;32(5):1254-66. doi: 10.1002/stem.1634.
PubMed 24449146
Study at a glance
From the registry record, last updated by the sponsor on 28 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy and Safety of Intra-articular Autologous Adipose-Derived Mesenchymal Stem Cell Injections for Improving Clinical Function in Patients With Knee Osteoarthritis: A Multicenter, Prospective, Randomized, Active-Controlled Trial
- ClinicalTrials.gov ID
- NCT07901790
- Acronym / sponsor ID
- 4-2026-0933
- Conditions
- Osteoarthritis, Knee, Knee Osteoarthritis
- Keywords
- Knee Osteoarthritis, Mesenchymal Stem Cells, Adipose-Derived Stem Cells, Intra-articular Injection, Hyaluronic Acid, WOMAC, Cartilage Regeneration
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 165 participants (estimated)
- Lead sponsor
- Yonsei UniversityUniversity, hospital or other
- Study start
- 3 Sep 2026 (actual)
- Primary completion
- 29 Feb 2028 (estimated)
- Study completion
- 31 May 2028 (estimated)
- First posted
- 28 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This multicenter, prospective, randomized, active-controlled, single-blind (assessor-blinded) clinical trial aims to evaluate the efficacy and safety of intra-articular injection of autologous adipose-derived mesenchymal stem cells (ADMSCs) compared with active comparator hyaluronic acid (HA) in patients with Kellgren-Lawrence grade II to III knee osteoarthritis. A total of 165 participants across 3 centers (Severance Hospital, Seoul National University Hospital, Inha University Hospital) will be randomly allocated to either the ADMSC group (1.0 x 10^8 cells, single injection) or the HA group (Synovian, 3 mL) in a 2:1 ratio and followed for 6 months post-injection.
Detailed description
Osteoarthritis (OA) is a prevalent degenerative joint disease characterized by progressive loss of articular cartilage, chronic pain, and joint dysfunction. Autologous adipose-derived mesenchymal stem cells (ADMSCs) offer potential cartilage protective and anti-inflammatory properties. In this confirmatory trial, 165 eligible adults aged 40 to 70 years with radiographic KL grade II or III knee OA and persistent pain (VAS >= 40 mm) will undergo abdominal fat harvest. Participants will be randomized 2:1 to receive either an ultrasound-guided intra-articular injection of autologous ADMSCs (1.0 x 10^8 cells suspended in 3 mL CryoStor 10) or high molecular weight cross-linked hyaluronic acid (Synovian 3 mL). Follow-up visits occur at 1, 3, and 6 months post-injection. The primary endpoint is the change from baseline in the WOMAC total score at 6 months. Secondary endpoints include changes in WOMAC subscales, VAS pain, KOOS subscores, responder rates (OMERACT-OARSI and MCID), structural outcomes on MRI (MOCART 2.0, MOAKS) and X-ray, rescue medication usage, exploratory synovial/serum biomarkers (COMP, CTX-II), and comprehensive safety profiles through 6 months. After completing the 6-month evaluation, participants allocated to the control group are offered autologous ADMSC injection.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- Parallel assignment with 2:1 randomization ratio to autologous ADMSC injection (1.0 x 10^8 cells) or active control hyaluronic acid (Synovian) injection.
| Arm | Type | Receives |
|---|---|---|
| Autologous ADMSC Injection | Experimental | Biological: Autologous Adipose-Derived Mesenchymal Stem Cells (ADMSCs)Arm Description: Participants receive a single ultrasound-guided intra-articular injection of autologous adipose-derived mesenchymal stem cells (1.0 x 10^8 cells/3 mL CryoStor 10) isolated and culture-expanded from the participant's abdominal subcutaneous adipose tissue. |
| Hyaluronic Acid Injection | Active comparator | Drug: Cross-linked Hyaluronic Acid (Synovian)Participants undergo identical abdominal liposuction and receive a single ultrasound-guided intra-articular injection of high-molecular-weight cross-linked hyaluronic acid (Synovian 3 mL). At the completion of the 6-month study period, cross-over autologous ADMSC injection is provided. |
Who may qualify
- Ages
- 40 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Adults aged 40 to 70 years at the time of written informed consent.
- Knee osteoarthritis diagnosed according to American College of Rheumatology (ACR) criteria with persistent knee pain for at least 3 months.
- Radiographic Kellgren-Lawrence (KL) grade II or grade III in the target knee.
- Activity pain score of >= 40 mm on a 100-mm Visual Analog Scale (VAS) in the target knee.
- Unilateral or bilateral knee OA. In bilateral cases, one target knee must be designated according to criteria 1-4 (if both knees meet criteria, the more painful/symptomatic knee is selected).
Key exclusion criteria (16 listed)
- Secondary knee osteoarthritis caused by infection, rheumatoid arthritis, or inflammatory joint disease.
- Pain caused by meniscus posterior horn root tear within 3 months prior to screening.
- Pain judged to be caused by subchondral insufficiency fracture or osteonecrosis.
- Conditions affecting joint pain or prognosis (e.g., gout, pseudogout, periarticular fracture, hemochromatosis, Wilson's disease, hypermobility, collagen gene disorders).
- Body Mass Index (BMI) >= 35 kg/m2.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Autologous Adipose-Derived Mesenchymal Stem Cells (ADMSCs)Also: ADMSCs, Autologous Adipose-derived Stem Cells, ADSC Intra-articular InjectionSingle intra-articular injection of 1.0 x 10^8 culture-expanded autologous ADMSCs suspended in 3 mL cryopreservation medium (CryoStor 10) under ultrasound guidance. | Biological | Autologous ADMSC Injection |
| Cross-linked Hyaluronic Acid (Synovian)Also: Synovian, High molecular weight crosslinked HA, Hyaluronic AcidSingle intra-articular injection of 3 mL high molecular weight cross-linked hyaluronic acid (Synovian Inj., LG Chem) administered under ultrasound guidance. | Drug | Hyaluronic Acid Injection |
Primary outcome
Change from Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Total Score at 6 Months
Time frame: Baseline and 6 months post-injection
The WOMAC total score assesses pain, stiffness, and physical function on a standardized scale. Higher scores indicate worse pain and functional limitation. The primary efficacy endpoint is the between-group difference in the change from baseline to 6 months post-injection, analyzed using analysis of covariance (ANCOVA).
8 secondary outcomes
Change from Baseline in WOMAC Subscale Scores
Time frame: Baseline, 1, 3, and 6 months post-injection
Change from Baseline in Visual Analog Scale (VAS) Pain Score
Time frame: Baseline, 1, 3, and 6 months post-injection
Change from Baseline in Knee Injury and Osteoarthritis Outcome Score (KOOS) Subscores
Time frame: Baseline, 1, 3, and 6 months post-injection
Proportion of Clinical Responders (MCID and OMERACT-OARSI criteria)
Time frame: 6 months post-injection
Magnetic Resonance Imaging (MRI) Assessment of Cartilage
Time frame: Baseline and 6 months post-injection
Radiographic Progression on Plain Radiographs (X-ray)
Time frame: Baseline, 3 months, and 6 months post-injection
Rescue Medication Usage
Time frame: Throughout the 6-month study period
Incidence and Severity of Adverse Events
Time frame: Throughout the 6-month study period
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Oct 2026.
- Background: PubMed 37367399Skidmore S, Hill MA, Bishara K, Konsek H, Kwon JH, Brockbank KGM, Rajab TK. Morbidity and Mortality of Heterotopic Partial Heart Transplantation in Rodent Models. J Cardiovasc Dev Dis. 2023 May 26;10(6):234. doi: 10.3390/jcdd10060234.
- Background: PubMed 31118076Servia L, Jove M, Sol J, Pamplona R, Badia M, Montserrat N, Portero-Otin M, Trujillano J. A prospective pilot study using metabolomics discloses specific fatty acid, catecholamine and tryptophan metabolic pathways as possible predictors for a negative outcome after severe trauma. Scand J Trauma Resusc Emerg Med. 2019 May 22;27(1):56. doi: 10.1186/s13049-019-0631-5.
- Background: PubMed 35467733Walshe EA, Romer D, Wyner AJ, Cheng S, Elliott MR, Zhang R, Gonzalez AK, Oppenheimer N, Winston FK. Licensing Examination and Crash Outcomes Postlicensure in Young Drivers. JAMA Netw Open. 2022 Apr 1;5(4):e228780. doi: 10.1001/jamanetworkopen.2022.8780.
- Background: PubMed 30873722Wang MK, Chin-Yee B, Lo CK, Lee S, El-Helou P, Alowami S, Gangji A, Ribic C. Crusted scabies in a renal transplant recipient treated with daily ivermectin: A case report and literature review. Transpl Infect Dis. 2019 Jun;21(3):e13077. doi: 10.1111/tid.13077. Epub 2019 Mar 29.
- Background: PubMed 24449146Jo CH, Lee YG, Shin WH, Kim H, Chai JW, Jeong EC, Kim JE, Shim H, Shin JS, Shin IS, Ra JC, Oh S, Yoon KS. Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a proof-of-concept clinical trial. Stem Cells. 2014 May;32(5):1254-66. doi: 10.1002/stem.1634.
- Individual participant dataSharing planned: Undecided. The plan to share individual participant data with other researchers has not yet been determined.
Related trials for Osteoarthritis
Recruiting
Effect of Anti-inflammatory Diet in Osteoarthritis
Osteoarthritis, Knee
Active, not recruiting
Effectiveness of Therapeutic Exercises on Spinopelvic Mobility
Osteoarthritis (OA) of the Hip
Active, not recruitingPhase 2/3
Single vs Triple Hyaluronic Acid in Knee Osteoarthritis
Osteoarthritis, Knee
Not yet recruiting
Holistic Healing for Knee Osteoarthritis
Knee Osteoarthritis (Knee OA)
RecruitingObservational study
Exploring Factors Linked to Worsening Over Time in People With Early-stage Knee Osteoarthritis and Those With Prior Proven Acute Knee Injury.
Knee Osteoarthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Autologous Adipose-Derived Mesenchymal Stem Cells (ADMSCs) and Cross-linked Hyaluronic Acid (Synovian) in people with Osteoarthritis and Knee, run by Yonsei University at 3 sites in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 28 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sung-Hwan Kim, M.D., Ph.D. (+82-2-2228-5679, orthohwan@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Total Score at 6 Months (time frame: Baseline and 6 months post-injection). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07901790, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Oct 2026; AzTrials last refreshed its copy on 7 Nov 2026.